Aquilo Capital Management LLC cut its holdings in shares of Loxo Oncology Inc (NASDAQ:LOXO) by 13.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,312 shares of the biopharmaceutical company’s stock after selling 17,500 shares during the period. Loxo Oncology makes up 7.8% of Aquilo Capital Management LLC’s portfolio, making the stock its 2nd biggest position. Aquilo Capital Management LLC’s holdings in Loxo Oncology were worth $18,674,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. boosted its position in shares of Loxo Oncology by 12.8% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 2,775 shares of the biopharmaceutical company’s stock valued at $474,000 after buying an additional 315 shares during the last quarter. First Mercantile Trust Co. boosted its position in shares of Loxo Oncology by 45.8% during the third quarter. First Mercantile Trust Co. now owns 1,029 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 323 shares during the last quarter. American International Group Inc. boosted its position in shares of Loxo Oncology by 3.2% during the third quarter. American International Group Inc. now owns 17,845 shares of the biopharmaceutical company’s stock valued at $3,048,000 after buying an additional 549 shares during the last quarter. Fortaleza Asset Management Inc. purchased a new stake in shares of Loxo Oncology during the second quarter valued at $110,000. Finally, Voya Investment Management LLC boosted its position in shares of Loxo Oncology by 0.4% during the second quarter. Voya Investment Management LLC now owns 186,422 shares of the biopharmaceutical company’s stock valued at $32,340,000 after buying an additional 661 shares during the last quarter. 93.39% of the stock is currently owned by institutional investors.

NASDAQ:LOXO traded down $15.66 on Wednesday, hitting $143.42. The stock had a trading volume of 549,868 shares, compared to its average volume of 406,983. The stock has a market capitalization of $4.94 billion, a price-to-earnings ratio of -27.01 and a beta of 2.26. Loxo Oncology Inc has a 52-week low of $71.45 and a 52-week high of $208.95.

Loxo Oncology (NASDAQ:LOXO) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.24). The firm had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $38.55 million. Loxo Oncology had a negative return on equity of 16.42% and a negative net margin of 43.49%. During the same period in the previous year, the business posted ($2.45) earnings per share. As a group, equities analysts forecast that Loxo Oncology Inc will post -2.52 earnings per share for the current year.

In other news, CEO Joshua H. Bilenker sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $166.20, for a total value of $3,324,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Jennifer Burstein sold 2,500 shares of the firm’s stock in a transaction dated Thursday, October 4th. The stock was sold at an average price of $164.92, for a total value of $412,300.00. Following the completion of the transaction, the vice president now directly owns 1,250 shares in the company, valued at approximately $206,150. The disclosure for this sale can be found here. Insiders sold 70,000 shares of company stock worth $11,618,850 over the last three months. Insiders own 17.10% of the company’s stock.

Several research firms recently commented on LOXO. William Blair reaffirmed a “buy” rating on shares of Loxo Oncology in a research report on Monday, October 22nd. Cowen reaffirmed a “buy” rating on shares of Loxo Oncology in a research report on Monday, October 22nd. Zacks Investment Research cut Loxo Oncology from a “hold” rating to a “sell” rating in a research report on Saturday. BidaskClub cut Loxo Oncology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 9th. Finally, Cann reissued a “buy” rating and issued a $202.00 target price on shares of Loxo Oncology in a research report on Monday, August 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $188.25.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2018/11/14/aquilo-capital-management-llc-reduces-position-in-loxo-oncology-inc-loxo.html.

About Loxo Oncology

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Featured Article: Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.